Insulin Eye Drops to Help Protect the Nerve in Open Angle Glaucoma
Tests insulin eye drops, taken once daily, in adults with open-angle glaucoma.
Plain-language title generated from the registry record
Registry title: Topical Insulin for Glaucoma (TING2)
Key facts
- Where
- Palo Alto, United StatesSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07619482, who can take part
Where in United States
- Byers Eye Institute at Stanford UniversityPalo Alto, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT07619482
- Record updated
- 13 October 2026
- Original description
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.Read full original descriptionShow less
A Phase 1/2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.
Limited Inclusion Criteria - All Groups:; Provide written informed consent approved by the appropriate ethics committee; Age 18 years or older; Understand study procedures and have the ability and willingness to abide by all procedures during the study; Capable of providing informed consent; Diagnosis of glaucoma; Only one eye per patient will be selected as the study eye; if both eyes meet inclusion criteria, the eye with worse visual acuity and/or visual field will be selected; Limited Exclusion Criteria - All Groups:; Pregnant or breastfeeding; Presence of any ocular pathology other than glaucoma that contributes to severe vision loss (retinopathy, maculopathy, severe uveitis, keratopathy, etc.); Diagnosis of glucose intolerance, type 1 or type 2 diabetes mellitus; Inability to perform reliable visual field testing; Unable to provide informed consent; Unable to complete the tests and follow-ups required by the study.